Max Gomez, Longtime TV Medical Reporter, Dies at 72

Known as Dr. Max (he was not a medical doctor. but had a Ph.D. in neuroscience), he reported on health and science with an easygoing gravitas.Max Gomez, an award-winning medical and science journalist who delivered informed reports for more than 40 years on TV stations in New York and Philadelphia, most recently during the Covid-19 pandemic, died on Sept. 2 at his home in Manhattan. He was 72.His partner, Amy Levin, said the cause was head and neck cancer, with which he had been diagnosed four years ago.Billed as “Dr. Max,” he brought an easygoing gravitas to reporting on subjects like vaccinations, knee replacements, prostate cancer, colonoscopies, sickle cell anemia and, when he himself contracted them, Lyme disease and the MRSA infection. One of his reports on Alzheimer’s disease focused on his father, a physician, who was swindled as his memory abandoned him.Dr. Gomez had been chief medical correspondent at WCBS, Channel 2, in New York City since 2007 and made his last appearance there in March 2022. He also worked at WNBC, Channel 4, and WNEW, Channel 5 (now WNYW), as well as KYW, Channel 3, in Philadelphia.“What he did best was to care deeply and combine that with being able to explain complex things so well that regular folks could understand them,” Dan Forman, a former managing editor of the Channel 2 news department, said by phone. “And he would activate it by helping viewers find the help they needed.”Dr. Gomez won seven local Emmy Awards in New York and two in Philadelphia, and some of his work was seen nationally, on the CBS News program “48 Hours” and on NBC News. He was also a semifinalist in NASA’s journalist-in-space program, which was suspended indefinitely after the shuttle Challenger exploded in 1986, and a co-author of three books, among them “Cells Are the New Cure: The Cutting-Edge Medical Breakthroughs That Are Transforming Our Health” (2017, with Dr. Robin L. Smith).He was a regular presence on Channel 2 from the start of the pandemic, when there were very few diagnosed Covid cases in the United States. For two years, as he dealt with cancer, he explained the medical issues facing viewers; showed how the coronavirus mutates; and sorted through infection data and studies.He was not a medical doctor — he had a doctorate in neuroscience — and he and the stations where he worked were sometimes criticized for referring to him as Dr. Max Gomez. “Max doesn’t tell people he’s an M.D., nor do we,” Paula Walker, then an assistant news director at Channel 4, told The Philadelphia Inquirer in 1991. “In our estimation, he’s probably more informed than the average health reporter.”Mr. Gomez in the studio of WCBS-TV in New York. He was a regular presence on the station from the start of the Covid-19 pandemic.via Gomez familyMaximo Marcelino Gomez III was born on Aug. 9, 1951, in Havana and moved to Miami with his family three years later. His father was an obstetrician and gynecologist; his mother, Concepción (Nespral) Gomez, worked for Cubana Airlines, Cuba’s national carrier, and later for Avianca, the largest airline in Colombia.After graduating from Princeton University in 1973 with a bachelor’s degree in geosciences, Dr. Gomez earned a Ph.D. in neuroscience from the Wake Forest University School of Medicine in 1978. He then became a National Institutes of Health postdoctoral fellow at Rockefeller University in Manhattan.While studying there, he chose not to pursue a career in research or academia, but rather to look for work in the media that would make use of his scientific background.“When I first decided to go after television, it was because I thought that if I didn’t, 20 years from now I’d be saying, ‘What if?’” he told The Philadelphia Daily News in 1985.He added: “Why television? Well, if I said money and ego aren’t part of it, then I’d be lying to you or to myself.”He contacted Mark Monsky, the news director of Channel 5’s “10 O’Clock News,” who gave him a one-month tryout in July 1980 that turned into a four-year stay. While there, Dr. Gomez was one of the first television reporters to focus on the AIDS crisis, according to Ms. Levin, who was then a producer at the station.Dr. Gomez moved to KYW in late 1984 and stayed there for six years. While there, he received an award from United Press International for his documentary on AIDS. He later received an award from New York City’s health department for his coverage of the 9/11 attacks while he was working for Channel 4.“Fear and anxiety levels were out of control in the city, but we were spending the first 20 minutes of every broadcast scaring the living daylights out of people,” he said in an interview in 2016 for the newsletter of CaringKind, an nonprofit Alzheimer’s caregiving organization, “and then, as my news director said, at the end of the show, I had 90 seconds to talk them off the ledge.”He moved to Channel 2 in 1994 and returned to Channel 4 in 1997 where, after nearly a decade, he was let go when the station cut costs. He came back to Channel 2 in 2007.In addition to Ms. Levin, Dr. Gomez is survived by a daughter, Katie Gomez; a son, Max IV; and a brother, George. His marriage to SuElyn Charnesky ended in divorce.In the 1985 Philadelphia Daily News interview, Dr. Gomez said that he viewed his role seriously: Being on television, he said, gave him credibility and a major responsibility.“I feel I owe it to people to be their first filter,” he said. “So if I’m talking about a health cure, I want to know where has this information been published. I present the best product I can. I know that it’s scientifically accurate.”

Read more →

These worms have rhythm

There’s a rhythm to developing life. Growing from a tiny cell cluster into an adult organism takes precise timing and control. The right genes must turn on at the right time, for the right duration, and in the correct order. Losing the rhythm can lead to diseases like cancer. So, what keeps every gene on beat?
Cold Spring Harbor Laboratory (CSHL) Professor Christopher Hammell has found that in the worm C. elegans, this genetic orchestra has no single conductor. Instead, a quartet of molecules works in concert to time each developmental stage. Hammell says this process shares some similarities with the circadian clocks that control human behavior. Understanding how the worm’s clock is regulated could help explain how time affects development in other animals. Hammell explains:
“This clock we’ve discovered sets the cadence of development. It’s a coordinator of the orchestra. It controls when the trombone goes, how loud it gets, and how long the note lasts.”
Each stage of C. elegans’ development begins with two proteins, NHR-85 and NHR-23. They work together to spark a pulse of gene expression, switching on the microRNA lin-4, which controls stem cell development patterns. The pulse’s timing, strength, and duration depend on the short stretch when NHR-85 and NHR-23 interact, and another protein, LIN-42, which ends each developmental period by shutting off NHR-85.
“Mess up the orchestra — it’ll still make sound,” Hammell says. “But the way the music changes lets us know proper timing is critical for development.”
Hammell teamed with Wolfgang Keil from Paris’ Curie Institute to observe this gene expression cycle in action. C. elegans takes about 50 hours to reach adulthood. During that time, it’s always on the move, like a restless teenager. The team developed a new imaging technique to hold the tiny worm in place long enough to take pictures and video. This let them measure each developmental beat as it occurred.
“We could see every time genes turned on from birth to adulthood,” Hammell says. “This kind of imaging had never been done in animals, only in single cells.”
Hammell is now working with CSHL Professor & HHMI Investigator Leemor Joshua-Tor to image how clock proteins interact over time.
“We want to work out, with even more precision, how this clock operates,” Hammell says. “Humans can do things like write music or perform calculus, not because we have a calculus or music gene, but because our developmental clocks enable our brain to develop longer into a more complex organ.”
In other words, when it comes to development, time is truly of the essence.

Read more →

Exercise-induced hormone irisin may reduce Alzheimer's disease plaque and tangle pathology in the brain

Researchers who previously developed the first 3D human cell culture models of Alzheimer’s disease (AD) that displays two major hallmarks of the condition — the generation of amyloid beta deposits followed by tau tangles — have now used their model to investigate whether the exercise-induced muscle hormone irisin affects amyloid beta pathology.
As reported in the journal Neuron, the Massachusetts General Hospital (MGH)-led team has uncovered promising results suggesting that irisin-based therapies might help combat AD.
Physical exercise has been shown to reduce amyloid beta deposits in various mouse models of AD, but the mechanisms involved have remained a mystery.
Exercise increases circulating levels of the muscle-derived hormone irisin, which regulates glucose and lipid metabolism in fat tissue and increases energy expenditure by accelerating the browning of white fat tissue.
Studies have revealed that irisin is present in human and mouse brains and that its levels are reduced in patients with AD and in mouse models of the condition.
To test whether irisin plays a causal role in the link between exercise and reduced amyloid beta, Se Hoon Choi, PhD and Eun Hee Kim, PhD, of the Genetics and Aging Research Unit at MGH, along with additional research colleagues applied the hormone to their 3D cell culture model of AD.
“First, we found that irisin treatment led to a remarkable reduction of amyloid beta pathology,” says Choi. “Second, we showed this effect of irisin was attributable to increased neprilysin activity owing to increased levels of neprilysin secreted from cells in the brain called astrocytes.”
Neprilysin is an amyloid beta-degrading enzyme that has been found to be elevated in the brains of mice with AD that were exposed to exercise or other conditions leading to reduced amyloid beta.

Read more →

New Covid variant BA.2.86 behind Norfolk care home outbreak

Published13 minutes agoShareclose panelShare pageCopy linkAbout sharingImage source, Getty ImagesBy Philippa RoxbyHealth reporterA new Covid variant is spreading in England and has led to an outbreak at a care home in Norfolk, UK health officials say.There have been 34 confirmed cases of BA.2.86, with 28 of those at the care home. There have been no deaths.It is too early to draw conclusions on whether it is more serious than past variants, the UK Health Security Agency (UKHSA) said.People eligible for a booster jab this autumn are encouraged to come forward.The government recently announced that the vaccine rollout would be earlier than planned because of the new variant. It will start next week.Who can get another Covid jab this autumn?The UK Health Security Agency’s latest briefing on Covid includes an analysis on BA.2.86, an Omicron spin-off.It says out of the 34 cases confirmed through sequencing in a lab, five people have needed hospital treatment.Norfolk County Council has been offering infection advice and support to the care home where there was an outbreak.Staff and residents were asked to have tests when an unusually high number of people became unwell, health officials say.Lab analysis found that BA.2.86 was confirmed in the majority of samples from those tests, they confirmed.This variant has been detected in a number of countries around the world. Dr Renu Bindra, incident director at UKHSA, said BA.2.86 had a significant number of mutations to the viral genome compared to other Covid variants circulating at the moment.But she added: “The data so far is too limited to draw firm conclusions about the impact this will have on the transmissibility, severity or immune escape properties of the virus.”Dr Bindra said it was likely to be some time before a confident assessment on that could be made.”It is clear that there is some degree of widespread community transmission, both in the UK and globally, and we are working to ascertain the full extent of this,” she said.Changing dates criticisedThe Department of Health and Social Care has been criticised for changing its mind on the start date of the autumn Covid and flu vaccine programme.It usually begins in early September, but was pushed back to October to increase protection in December and January when flu and Covid are more likely to cause problems.The timing has now changed again, to 11 September, because of concerns over the new variant.Pharmacists said last week that they had been left with very little time to prepare for the rollout of Covid and flu vaccines.People who are eligible for a Covid-19 vaccine include:residents in a care home for older adultsall adults aged 65 years and overanyone aged six months to 64 years in a clinical risk groupfront-line health and social care workersanyone aged 12 to 64 years who lives in the same house as people with weakened immune systemsMore on this storyWho can get another Covid jab this autumn?Published2 days agoCovid and flu winter jabs to be brought forwardPublished30 AugustWhat did the government do about Covid and care homes?Published1 March

Read more →

Study links epigenetic changes to historic trauma in Alaska Native communities

Researchers investigated the relationship between historical traumatic events experienced by Alaska Native communities and epigenetic markers on genes that previous studies have linked to trauma. The new study found a similar pattern among Alaska Native participants, with specific epigenetic differences observed in those who reported experiencing the most intense symptoms of distress when reflecting on historic losses.
The study also found that individuals who strongly identified with their Alaska Native heritage and participated in cultural activities generally reported better well-being. The new findings are detailed in the International Journal of Health Equity.
The study is the result of a close collaboration between the scientists and members of two Alaska Native communities. The Native Nations guided the design and interpretation of the study and retain control of all of the data, in accordance with principles of Indigenous data sovereignty, said Ripan Malhi, a professor of anthropology at the University of Illinois Urbana-Champaign and corresponding author of the new study.
While DNA sequence remains stable throughout the lifespan, small chemical modifications to specific genes can turn up or turn down the expression of those genes, said study lead author Mary LaVanne, who conducted the analysis while a postdoctoral researcher at the U. of I.
“These epigenetic modifications are often studied in response to severe changes in lived environments,” LaVanne said. “Epigenetic alterations can persist throughout the lifespan and are sometimes maintained over multiple generations.”
Research on epigenetic changes in response to trauma is in its infancy, but studies involving other groups have found trauma-related modifications to genes involved in homeostasis, the immune response, the stress response and other functions, Malhi said.
Native communities in Alaska have experienced centuries of disruptive violence, disease and displacement, largely resulting from colonial expansion into the Americas and centuries of mistreatment well beyond the colonial era.

Read more →

Mums exposed to air pollution give birth to smaller babies, but living in a greener area may mitigate the risks

Women exposed to air pollution give birth to smaller babies, according to research that will be presented at the European Respiratory Society International Congress in Milan, Italy. The research also shows that women living in greener areas give birth to bigger babies and this may help counteract the effects of pollution.
There is a strong relationship between birthweight and lung health, with low birthweight children facing a higher risk of asthma and higher rates of chronic obstructive pulmonary diseases (COPD) as they grow older.
Researchers say there is a need to reduce air pollution and make towns and cities greener to help protect babies and their developing lungs from potential harm.
The study was based on data from the Respiratory Health in Northern Europe (RHINE) study and presented by Mr Robin Mzati Sinsamala, a researcher in the Department of Global Public Health and Primary Care at the University of Bergen (UiB), Norway. It included 4286 children and their mothers living in five European countries (Denmark, Norway, Sweden, Iceland and Estonia).
The researchers gauged the greenness of the areas where the women were living during pregnancy by measuring the density of vegetation on satellite images. This vegetation includes forests and farmland as well as parks in urban areas. The researchers also used data on five pollutants: nitrogen dioxide (NO2), ozone, black carbon (BC), and two types of particulate matter (PM2.5 and PM10). The average levels of air pollution were within European Union standards. Researchers compared this information with the babies’ birthweights, taking account of factors that are known to affect birthweight, such as mother’s age, whether the mothers smoked or had any other health conditions.
They found that higher levels air pollution were linked with lower birthweights, with PM2.5, PM10,NO2 and BC associated with average reductions in birth weight of 56g, 46g, 48g and 48g, respectively. When researchers took greenness into account, the effect of air pollution on birthweight was reduced. Women who lived in greener areas had babies with slightly higher birth weight (27g heavier on average) than mothers living in less green areas.
Mr Sinsamala said: “The time when babies are growing in the womb is critical for lung development. We know that babies with lower birthweight are susceptible to chest infections, and this can lead on to problems like asthma and COPD later on.

Read more →

New at-home test for gingivitis protects oral health

Engineers at the University of Cincinnati have developed a new device that can warn consumers about early risks of tooth decay from diseases such as gingivitis and periodontitis.
Gingivitis, the earliest form of gum disease, is caused by bacteria. But not just any bacteria.
The problem for researchers was getting a device to single out the particular type responsible for the disease, said Andrew Steckl, an Ohio Eminent Scholar and distinguished research professor in UC’s College of Engineering and Applied Science.
“It’s been quite the challenge to get to the point where we can detect this toxin created by the bacteria responsible for gingivitis,” he said.
Steckl and UC Senior Research Associate Daewoo Han collaborated with Sancai Xie, a principal scientist at Procter & Gamble Co., and described their results in a paper published in the Royal Society of Chemistry journal Sensors and Diagnostics.
Steckl’s research team has been exploring biosensing for various applications. They studied stress hormones in sweat in collaboration with the Air Force Research Lab at Wright-Patterson Air Force Base. Now they are studying saliva.
“There are good reasons to use saliva,” he said. “It’s relatively plentiful and easy to obtain through noninvasive methods. And saliva has a lot of important elements that can act as indicators of your health.”
Bacteria from gingivitis can travel through the bloodstream, leading to cardiovascular disease and other serious health problems, Steckl said.

Read more →

Scientists unlock secrets of red blood cell transporter, potentially paving the way for new drugs

Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs. Details on the findings, which were reported in the September 7 issue of Nature Structural & Molecular Biology, could lead to the development of more targeted medicines.
The research team, led by Daniel Wacker, PhD, Bin Zhang, PhD, and Avner Schlessinger, PhD, found that this transporter facilitates the movement of a substance called bicarbonate, which certain drugs can inhibit. They discovered how these drugs block the transporter and devised novel compounds capable of achieving the same effect.
“Our findings provide a detailed understanding of how bicarbonate transporters work, and the newly identified tool compounds open doors to studying conditions involving red blood cells, including hemolytic anemias,” says Dr. Wacker, corresponding author and an Assistant Professor of Pharmacological Sciences, Neuroscience, and Genetic and Genomic Sciences at Icahn Mount Sinai.
Previously, human bicarbonate transporters were poorly understood, despite being involved in many aspects of human physiology, including regulating pH that involves keeping the level of acidity within a specific range.
Using cryo-electron microscopy, the team identified high-resolution structures revealing bicarbonate and inhibitor binding, and their impact on the transport mechanism. With these insights, the researchers used computer simulations to analyze millions of compounds that could interact with the substrate binding site.
Their experiments pinpointed a group of innovative chemical inhibitors specifically designed for anion exchanger 1, a protein that is crucial for maintaining the proper function of the blood and red blood cells.
“Our study also demonstrates the potential for developing new inhibitors with medical potential for other solute carrier (SLC) proteins, a protein family gaining importance in drug development,” says co-author Dr. Zhang, the Willard T.C Johnson Research Professor of Neurogenetics and Director of the Mount Sinai Center for Transformative Disease Modeling at Icahn Mount Sinai.

Read more →

CAR-T-cell therapy without side effects? Researchers show results in preclinical models

When Richard O’Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy easier on patients.
What he didn’t expect was that a side project — worked on by Megan Tennant, a graduate student in his lab, as a way to keep busy while a key piece of equipment was being serviced — would potentially open up this treatment beyond the world of cancer.
“I don’t think that either of us expected that first initial experiment to work,” Tennant said. “But when we saw how well it worked and really started to conceptualize where this could go and how important this could be, it was exciting.”
O’Neil said they’ve begun conversations with biotechnology companies about how to push forward their findings.
“Right now, we’re trying to out-license the technology,” O’Neil added. “The most interest, actually, has come in the context of lupus.”
CAR-T-cell therapy is currently used to treat some types of blood cancers that have returned after treatment or that haven’t responded to chemotherapy. It is both expensive and extensive — some of a patient’s T-cells are removed and sent to a lab where, in a process that can take several weeks, they’re engineered to add chimeric antigen receptors (CAR) that are tuned to home in on specific proteins on the surface of cancer cells. The newly formed CAR-T-cells are then reinfused into the patient to attack the cancer.
Some patients have experienced incredible recoveries after CAR-T-cell therapy. But they’ve also endured incredibly strong and scary side effects, in part because of the lymphodepleting chemotherapy that is performed before the CAR-T-cells are reinfused.

Read more →

Study suggests energy-efficient route to capturing and converting CO2

In the race to draw down greenhouse gas emissions around the world, scientists at MIT are looking to carbon-capture technologies to decarbonize the most stubborn industrial emitters.
Steel, cement, and chemical manufacturing are especially difficult industries to decarbonize, as carbon and fossil fuels are inherent ingredients in their production. Technologies that can capture carbon emissions and convert them into forms that feed back into the production process could help to reduce the overall emissions from these “hard-to-abate” sectors.
But thus far, experimental technologies that capture and convert carbon dioxide do so as two separate processes, that themselves require a huge amount of energy to run. The MIT team is looking to combine the two processes into one integrated and far more energy-efficient system that could potentially run on renewable energy to both capture and convert carbon dioxide from concentrated, industrial sources.
In a study appearing today in ACS Catalysis, the researchers reveal the hidden functioning of how carbon dioxide can be both captured and converted through a single electrochemical process. The process involves using an electrode to attract carbon dioxide released from a sorbent, and to convert it into a reduced, reusable form.
Others have reported similar demonstrations, but the mechanisms driving the electrochemical reaction have remained unclear. The MIT team carried out extensive experiments to determine that driver, and found that, in the end, it came down to the partial pressure of carbon dioxide. In other words, the more pure carbon dioxide that makes contact with the electrode, the more efficiently the electrode can capture and convert the molecule.
Knowledge of this main driver, or “active species,” can help scientists tune and optimize similar electrochemical systems to efficiently capture and convert carbon dioxide in an integrated process.
The study’s results imply that, while these electrochemical systems would probably not work for very dilute environments (for instance, to capture and convert carbon emissions directly from the air), they would be well-suited to the highly concentrated emissions generated by industrial processes, particularly those that have no obvious renewable alternative.

Read more →